Connect to share and comment

FTSE snaps three-day rally after miner weakness

By Alistair Smout LONDON (Reuters) - The FTSE 100 fell on Friday after a three-day rally, as investors backed away from riskier sectors and U.S. GDP figures came in below expectations. Material and energy stocks, which are sensitive to optimism over the global economic outlook, took 26 points off the FTSE 100, dragging the index into negative territory.

European shares just up, awaiting Italy polls

* FTSEurofirst 300 up 0.2 percent * Investors eye outcome of Italy election * Viviendi rises on reports of stake sale * Pearson, AB Foods drop after updates By David Brett LONDON, Feb 25 (Reuters) - European shares added to a cautious recovery from multi-month lows early on Monday ahead of the end of voting in a closely-fought election in Italy, seen as crucial to efforts to dig the euro zone out of crisis.

UPDATE 2-Reckitt loses U.S. bid to block generic heroin addict drug

* FDA rejects Reckitt petition on heroin addiction drug packaging * FDA approves two generic versions of Reckitt's Suboxone * FDA refers Reckitt to competition regulator * Shares in Reckitt down 3.6 pct By Rosalba O'Brien LONDON, Feb 25 (Reuters) - U.S. regulators approved two generic versions of Reckitt Benckiser's heroin addiction drug and rejected its bid to block rival products on the grounds that stricter packaging rules were needed to protect children.

Britain's FTSE dips in early deals as ex-divs weigh

LONDON, Feb 20 (Reuters) - Britain's leading blue-chip index fell in early trade on Wednesday, as a number of heavyweight firms traded ex-dividend, taking the FTSE back from the 5-year highs hit in the previous session. Ex-dividend factors took around 8 points off the index, enough to take it into negative territory, as Barclays, Carnival, GlaxoSmithKline and Reckitt Benckiser all traded without entitlement to their latest payout. Barclays, GSK and Reckitt were three of the top four fallers on the index in early trade.

UPDATE 2-Heavy flu season helps Reckitt beat profit forecasts

* FY adjusted EPS 264 pence vs forecast 249 pence * Q4 sales growth ex-pharma 6 pct, Europe & N. America 3 pct * Makes 'modest' buy of Chinese traditional medicine firm By Rosalba O'Brien LONDON, Feb 13 (Reuters) - An unusually severe cold and flu season in the United States helped drive full-year profits higher at Britain's Reckitt Benckiser, maker of Strepsils throat lozenges and Mucinex decongestant.

Reckitt Benckiser says 2012 profits edge up

Reckitt Benckiser, the household goods and drugs group, said on Wednesday that net profits rose last year thanks to strong global demand for its health and hygiene products. Earnings after taxation increased by 4.8 percent to £1.83 billion ($2.87 billion, 2.13 billion euros) in 2012, compared with £1.75 billion in 2011, Reckitt said in a results statement. The maker of Dettol surface cleaners, Durex condoms and Nurofen pain relief pills, added that revenues grew 1.0 percent to £9.56 billion.

Reckitt Benckiser says 2012 profits edge higher

Reckitt Benckiser, the household goods and drugs group, said on Wednesday that net profits rose last year thanks to strong global demand for its health and hygiene products. Earnings after taxation increased by 4.8 percent to £1.83 billion ($2.87 billion, 2.13 billion euros) in 2012, compared with £1.75 billion in 2011, Reckitt said in a results statement. The Anglo-Dutch maker of Dettol surface cleaners, Durex condoms and Nurofen pain relief pills, added that revenues grew 1.0 percent to £9.56 billion.
Syndicate content